Montelukast API Market Research Report - Global Forecast till 2023

Montelukast API Market: Information By Application (Asthma, Allergic Rhinitis, Bronchospasm, Urticaria, Others) and Region (North America, Europe, Asia-Pacific and the Middle East & Africa) - Global Forecast till 2023

ID: MRFR/HC/6414-CR | May 2019 | Region: Bric | 94 pages

Market overview
Global Montelukast API Market is expected to reach USD 1,430.215 Thousand by 2023 with a CAGR of 3.38%. Montelukast API is a leukotriene receptor antagonist, which is basically a medication highly used for the maintenance treatment of the disease called asthma. Apart from this, it is also used for alleviating the symptoms of allergic rhinitis and hay fever. Montelukast API is a drug that blocks leukotrienes that are responsible for asthma or which are responsible to worsen asthma, it also helps to cure all asthma-related allergies asthma. Montelukast API decreases inflammation in the airways.
According to the reports of the World Health Organization (WHO), about 235 million people across the globe are suffering from asthma. The lower-middle-income countries are facing the maximum death rates with asthma, about 80% of the total asthma patients die in low-income countries. Montelukast API is used to treat various illness caused by asthma which includes coughing, chest tightness, wheezing, and difficulty in breathing or short breathing. Based on the reports of the Centers for Disease Control and Prevention (CDC), every year, about 9.8 million asthma patients visit doctor’s offices, 1.8 million emergency visits, and 188,968 discharges from the hospitals. 1 out of every 13 people is suffering from asthma. According to the reports, in 2017, 25 million Americans were asthma patients, 8.4% of children and 7.7% of adults. There are about 6.2 million children, suffering from asthma that is under 18 years old. The usage of montelukast sodium is also increasing due to the growing generality of asthma globally.
Montelukast API market value is increasing with the increasing numbers of asthma patients around the globe due to the high demand for montelukast sodium. The side effects of the montelukast sodium which includes heartburn, nausea, upset stomach, and stomach pain, availability of the proxy products in the market, and the unfavorable effect of the drugs are likely to restrain the market growth. The presence of leukotriene inhibitory agent in montelukast sodium is used to treat primary dysmenorrheal, urticaria, exercise-induced bronchospasm, apart from asthma. It is used to prevent breathing problems and shortness of breath.
 This report contains all the information on the montelukast API market research and the strength of the montelukast sodium in the market. The report also contains the culmination of dynamics, segmentation, key players, regional analysis, and other important factors. A detailed analysis of the montelukast API globally and forecast to 2023 is also included in the report.
Covid 19 Analysis
Since the beginning of the covid 19 pandemic, the average prices of the montelukast API market companies have increased by 10% to 15% on an average. In some cases, the increase in the prices was more than 50%. Hydroxychloroquine holds the highest price in the market with a hike of 600%, which is followed by Nimesulide and Azithromycin, with a price hike of 185% and 95%. On the other hand, API price hikes include Ornidazole with a hike of 73%, Paracetamol with a hike of 62%, Montelukast sodium with a hike of 52 %, and Penicillin with a hike of 40 %
The use of compound drugs to treat the covid 19 patients in the hospitals has been permitted by the FDA, due to this; there is a shortage in the supply chain of the montelukast API. The other factors; like the availability of substitutes in the market and the side effects of the montelukast sodium are deriving the growth of the market.
Market Dynamic

        Drivers

The rising geriatric population along with the increasing respiratory diseases is expanding the growth of the montelukast API market size. Montelukast sodium is used to treat virus-related wheezing, it is a clinically approved drug that provides effective treatment for diseases related to asthma and its side effects. Mantekulast sodium helps relieve symptoms of wheezing; it also decreases the incidence rates of infantile asthma and also improves the function of the lungs.
Thus, the multiple benefits of montelukast sodium are increasing the growth of the montelukast API marker during the forecast period.

        Opportunities

The advancement of the technologies has benefited the growth of the global market of montelukast API tremendously. The rising generality of asthma is the major cause for the growth of the market. The increasing allergic diseases and the usage of the montelukast sodium to prevent bronchospasm is expected to boost the growth of the market.
In 2019, Montekulst sodium Amorphous held the maximum shares in the global montelukast sodium market and it is expected to grow at a CAGR of 6.31% during the forecast period.

        Restraints

The availability of the proxy product in the market has created hurdles for the Montekulast API market value; the unfavorable effects of the montelukast sodium is predicted to restrains the growth of the market. The lack of awareness among the people regarding the drug, and the side effects of the existing products which include heartburn, nausea, stomach pain, and diarrhea is estimated to create hurdles in the growth of the Montelukast sodium market

        Challenges

The increasing side effects of the drug and the lack of awareness among the people are the major hurdles in the growth of the market.

        Cumulative Growth Analysis

The growing cases of asthma are predicted to lead the graph of the market. Although, the unfavorable side effects of the drug and the availability of the proxy product in the market is likely to detain the graph of the market. 
The global market of montelukast API is anticipated to reach USD 1,430,215.2 thousand by the end of 2023 with a growth rate of CAGR of 3.38% due to the high demand for the drug globally to treat asthma patients. The use of montelukast sodium in the treatment of allergic rhinitis cases are magnifying the growth of the market, and it’s expected to display a CAGR of 3.11% from 2018 to 2023.
Value Chain Analysis
The segments of asthma are predicted to lead the way and register a considerable CAGR to reach USD 700,730.7 thousand by the end of 2023. Mantekulast sodium helps to prevent bronchoconstriction, it occurs after or during the exercise and it causes shortness of breathing or cough.  Mumntekulast is a category of medicine that is called leukotriene receptor antagonists.
The highest growing segment of montelukast sodium is the montelukast sodium amorphous and it is predicted to register the highest CAGR during the forecast period 2020 – 2025. The allergic rhinitis cases are increasing and it’s driving the growth of the market, it is estimated to exhibit the highest CARG of 3.11% from 2018 to 2023
 Segmentation Overview
Montelukast sodium amorphous is an anti-allergic, anti-asthmatic, cytoprotective agent, and anti-inflammatory which is very useful in the treatments of different diseases. Mankekulast sodium amorphous segment held the maximum share in the year 2019, and it is predicted to grow at a CARG of 6.31% during the forecast period.

        By Application

On the basis of application, montelukast API is segmented into four types, allergic rhinitis, bronchospasm, urticaria, and others.  Allergic rhinitis segments held the largest share in the global montelukast sodium market, 2019. It is estimated to register the highest CAGR during the forecast period.

        By End-Users

On the basis of geography, the market is segmented into five regions, North America, Europe, Asia Pacific, the middle east and Africa, and Latin America
Regional Analysis
In 2017, North America held the largest shares in the global API market, shares of 39.25%, and the regional market is predicted to register a CAGR of 3.12% during the forecast period. On the other hand, the fastest CAGR is predicted to be registered by Asia-pacific. During the forecast period from 2018 to 2023, the Chinese market is expected to exhibit the highest growth rate of 5.10%
The European market is predicted to exceed or reach USD 396,258 thousand by the end of 2023. The United Kingdom is the major contributor after America and Europe to the growth of the global regional market, followed by France. The increasing cases of COPD, asthma, and allergies, and montelukast therapeutic use are the major factor for the growth of the montelukast API market.
Competitive landscape
Launches of the products, acquisitions and mergers, joint ventures, and R&D are the key strategies adopted by the key players of the global montelukast API market.
The major key players of the global market montelukast API market are as follows:

        Sandoz International GmbH (Germany)
Teva Pharmaceutical Industries Ltd (Israel)
Dr. Reddy’s Laboratories Ltd (India)
Morepen Laboratories Ltd (India)
Mylan N.V. (US)
Teva Pharmaceutical Industries Ltd (Israel)
Vintage Pharmaceuticals Inc (US)
Hikma Pharmaceuticals PLC (UK)
Glenmark (India)
Merck Sharp and Dohme Corp (US)
Sandoz International GmbH (Germany)
Hetero (India) and Aurobindo Pharma (India)

 Recent Developments

        In February 2019, Sandoz International acquired Aspen Global Incorporated.
        In August 2016, Teva Pharmaceutical Industry Ltd acquires Actavis Generics.

Global Montelukast API Market, By Application

        Asthma
        Allergic
         Rhinitis
        Bronchospasm
        Urticaria
        Others

Global Montelukast API Market, By Region

North America

US
Canada

Latin America
Europe

Germany
UK
France
Spain
Italy
Eastern Europe
Rest of Europe

Asia-Pacific

China
India
Japan
Rest of Asia-Pacific

Middle East & Africa

Middle
EastAfrica